Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
During a previous therapeutic trial, investigators showed that the bumetanide improved
significantly autism. This trial showed that a therapeutic response was obtained in 75% of
cases.
These first results were reinforced by a study led with adult patients for whom the eye
tracking measurements as well as the functional MRI showed a diminution of the response time
and a modification (amplification) of the cerebral response during an emotions recognition
test.
Finally, investigators confirmed the physiological mechanism behind the action of the
bumetanide in a study in two mouse models of autism.